CombiGene
6,96 SEK +3,11 %Vær den første som følger denne virksomhed
CombiGene is a gene therapy company that focuses on developing new treatments intended for diseases related to the central nervous system and metabolic diseases. The company focuses on drug-resistant focal epilepsy and partial lipodystrophy, respectively. CombiGene collaborates with several actors in both academia and industry. The company is headquartered in Lidingö.
Omsætning
26,7 mio.
EBIT %
-26,03 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
COMBI
Daglig lav / høj pris
6,62 / 7
SEK
Markedsværdi
137,82 mio. SEK
Aktieomsætning
80,87 t SEK
Volumen
12 t
Finanskalender
Delårsrapport
25.08.2023
Delårsrapport
10.11.2023
Årsrapport
16.02.2024
Viser Alle indholdstyper